Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
Details· BAT2206 is Bio-Thera Solution s ’ third EC approved product Guangzhou,China– August , 2024 – Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and biosimilars, today announced that the EC has approvedBAT2206 (usteki...
BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
Guangzhou, China/Bad Vilbel, Germany – 22 August 2025 – Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, and global specialty, generic and consumerhealthcare medicines company STADA Arzneimittel AG have agr...